Private Wealth Partners LLC Purchases 28,031 Shares of Pfizer Inc. $PFE

Posted by on Jul 5th, 2026

Private Wealth Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 4.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 604,878 shares of the biopharmaceutical company’s stock after acquiring an additional 28,031 shares during the period. Pfizer accounts for approximately 1.3% of Private Wealth Partners LLC’s portfolio, making the stock its 23rd largest holding. Private Wealth Partners LLC’s holdings in Pfizer were worth $16,985,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PFE. Revisor Wealth Management LLC lifted its stake in shares of Pfizer by 1.4% during the 1st quarter. Revisor Wealth Management LLC now owns 31,029 shares of the biopharmaceutical company’s stock valued at $871,000 after buying an additional 415 shares in the last quarter. Koshinski Asset Management Inc. grew its stake in Pfizer by 34.6% in the 1st quarter. Koshinski Asset Management Inc. now owns 53,829 shares of the biopharmaceutical company’s stock valued at $1,512,000 after buying an additional 13,843 shares in the last quarter. V Square Quantitative Management LLC grew its stake in Pfizer by 14.1% in the 1st quarter. V Square Quantitative Management LLC now owns 59,682 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 7,372 shares in the last quarter. Cumberland Advisors Inc. raised its holdings in Pfizer by 9.2% during the 1st quarter. Cumberland Advisors Inc. now owns 53,300 shares of the biopharmaceutical company’s stock valued at $1,497,000 after acquiring an additional 4,500 shares during the period. Finally, Nixon Peabody Trust Co. lifted its position in shares of Pfizer by 7.1% during the first quarter. Nixon Peabody Trust Co. now owns 8,713 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 578 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.1%

Pfizer stock opened at $24.29 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The stock has a market cap of $138.45 billion, a P/E ratio of 18.54 and a beta of 0.35. The firm’s fifty day moving average price is $25.63 and its 200-day moving average price is $26.23.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the company earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Morgan Stanley raised their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Finally, Guggenheim increased their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.82.

Get Our Latest Stock Report on PFE

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.